Company Overview and News

0
FinMin seeks more time for PSBs to meet MPS norm

7h freepressjournal.in
New Delhi : The finance ministry may approach markets regulator Sebi to seek relaxation on the minimum 25 per cent public shareholding norm for some state banks (PSBs).
INDIANB IOB 500116 UDBKL IDBI UBLS 532418 532814 532505 CNRYY 532388 SYNDIBANK 532276 532121 532483 UBLA UCOBANK CANBK DENABANK ANDHRABANK

0
5 state banks  to get Rs 11,336-cr capital infusion

7h freepressjournal.in
New Delhi : The finance ministry on Tuesday approved infusion of Rs 11,336 crore in five state-owned lenders including PNB, Corporation Bank and Andhra Bank to help them meet regulatory capital requirement, sources said.
532179 532388 IOB PNJZY 532461 CRPKY 532480 532418 ALBK PNB CORPBANK ANDHRABANK

0
Finance Ministry approves Rs 11,336 crore capital infusion in 5 PSU Banks

7h freepressjournal.in
New Delhi: The finance ministry today approved infusion of Rs 11,336 crore in five state-owned lenders including PNB, Corporation Bank and Andhra Bank to help them meet regulatory capital requirement, sources said. This is the first ever capital infusion in the current fiscal and the remaining amount of Rs 53,664 crore would be disbursed during the course of the year. As per the plan, the sources said, Punjab National Bank (PNB), hit by Nirav Modi scam, will get the highest amount of Rs 2,816 crore out, while Allahabad Bank to get Rs 1,790 crore.
532179 532388 IOB PNJZY 532461 CRPKY 532480 532418 ALBK PNB CORPBANK ANDHRABANK

0
Andhra Bank - News Clarification

7h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532418 ANDHRABANK

0
Andhra Bank - News Clarification

13h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532418 ANDHRABANK

0
India Poised to Infuse $2 Billion Into State-Run Banks - Bloomberg

2018-07-18 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
532179 532388 IOB PNJZY 532461 CRPKY 532418 PNB CORPBANK ANDHRABANK

0
Finmin to provide capital to more banks by September

2018-07-18 moneycontrol
After approving capital support for five public sector banks (PSBs), the finance ministry is assessing the needs of 2-3 more banks and fund infusion in them would be done by the end of the second quarter of the current fiscal.
532179 532388 IOB PNJZY 532461 CRPKY 532480 532418 ALBK PNB CORPBANK ANDHRABANK

0
Rs 5,000 cr bank loan fraud case: Charge sheet against Gujarat-based pharma firm’s director

2018-07-18 freepressjournal.in
New Delhi: The Enforcement Directorate has filed a charge sheet against Gujarat-based pharma firm Sterling Biotech Limited’s director Rajbhushan Omprakash Dixit in a bank loan fraud case of over Rs 5,000 crore. The charge sheet was filed before Additional Sessions Judge Satish Arora by special public prosector Nitesh Rana and advocate A R Aditya.
SLTHY STERLINBIO 512299 532418 ANDHRABANK

0
ED chargesheet against Sterling Biotech director in bank loan fraud case

2018-07-18 livemint
New Delhi: The Enforcement Directorate has filed a chargesheet against Rajbhushan Omprakash Dixit, director of Gujarat-based pharmaceutical firm Sterling Biotech, in a case involving bank loan fraud of over ₹5,000 crore.
SLTHY STERLINBIO 512299 532418 ANDHRABANK

0
PSU banks jump as FinMin okays capital infusion of Rs 11,336 cr

2018-07-18 thehindubusinessline
Shares of state-run lenders jumped on reports of capital infusion infusion into 5 PSU banks. Nifty PSU bank index gained as much as 1.5 per cent.
532179 532388 IOB PNJZY 532461 CRPKY 532480 532418 ALBK PNB CORPBANK ANDHRABANK

0
News In Numbers: Tesla Model 3 exceeds 30% net profit margin

2018-07-18 livemint
What is it? The amount Indian government plans to infuse into five public sector banks in the next few days.
532388 IOB PNJZY 532461 532418 PNB ANDHRABANK

0
5 state banks  to get Rs 11,336-cr capital infusion

2018-07-18 freepressjournal.in
New Delhi : The finance ministry on Tuesday approved infusion of Rs 11,336 crore in five state-owned lenders including PNB, Corporation Bank and Andhra Bank to help them meet regulatory capital requirement, sources said.
532179 532388 IOB PNJZY 532461 CRPKY 532480 532418 ALBK PNB CORPBANK ANDHRABANK

0
PNB, IOB, Andhra Bank, Corporation Bank, Allahabad Bank up 4-13% post capital infusion

2018-07-18 moneycontrol
Share price of PNB, IOB, Andhra Bank, Corporation Bank and Allahabad Bank reacted positively on the government capital infusion plan.
532179 532388 IOB PNJZY 532461 CRPKY 532480 532418 ALBK PNB CORPBANK ANDHRABANK

0
Finance Ministry approves Rs 11,336 crore capital infusion in 5 PSU Banks

2018-07-18 freepressjournal.in
New Delhi: The finance ministry today approved infusion of Rs 11,336 crore in five state-owned lenders including PNB, Corporation Bank and Andhra Bank to help them meet regulatory capital requirement, sources said. This is the first ever capital infusion in the current fiscal and the remaining amount of Rs 53,664 crore would be disbursed during the course of the year. As per the plan, the sources said, Punjab National Bank (PNB), hit by Nirav Modi scam, will get the highest amount of Rs 2,816 crore out, while Allahabad Bank to get Rs 1,790 crore.
532179 532388 IOB PNJZY 532461 CRPKY 532480 532418 ALBK PNB CORPBANK ANDHRABANK

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...